Why the study?
Does olmesartan medoxomil reduce vascular inflammation markers in patients with essential hypertension and microinflammation?
Population
199 patients with essential hypertension and microinflammation (olmesartan n=100, placebo n=99)
Comparison
Olmesartan medoxomil for 12 weeks, with… vs Placebo for 12 weeks, with pravastatin added at…
Design
RCT, double-blind
Follow-up
12 weeks
Authors
Loading...
Olmesartan reduces vascular inflammatory markers independent of BP effects in hypertension; extends evidence for pleiotropic ARB actions on microinflammation.
Does olmesartan medoxomil reduce vascular inflammation markers in patients with essential hypertension and microinflammation?
Angiotensin II receptor blockade with olmesartan significantly reduces vascular microinflammation in hypertensive patients, independent of blood pressure reduction.
Fliser et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: